IVI in the Media
South China Morning Post | The latest coronavirus boosters target Omicron. Are they safe and effective?
South China Morning Post | Scientists urge people to take second Covid vaccine booster if offered as Omicron continues to spread
Chosun Ilbo | Jerome Kim, Director General of International Vaccine Institute, named a distinguished professor at Seoul National University
Financial Times | South Korea downgrades Covid to a ‘Class 2’ disease and removes restrictions
South China Morning Post | China was the world’s biggest Covid-19 vaccine exporter. Not any more
The Wall Street Journal | Despite High Covid-19 Case Counts, Asian Nations Learn to Live With the Virus
Barron’s | China Eases Some Covid Testing Rules. It’s a Targeted Approach to Reduce Impact on the Economy.
CNBC | We need to treat Covid as an endemic pathogen and update vaccines: International Vaccine Institute
ADB Insight | Year of the Vaccine: The Next Steps for Asia and the Pacific to Combat COVID-19
The Telegraph | South Korea abandons its successful test and trace system as omicron cases surge
South China Morning Post | Can China’s home-grown mRNA Covid-19 vaccine pass its final tests?
The Telegraph | Vaccine hesitancy among Taiwan’s elderly mars its pandemic performance and prevents reopening
South China Morning Post | Which vaccines stop Omicron? Search for data moves from labs to real world
South China Morning Post | As Omicron upends Covid-19 vaccine targets, what will the future look like?
South China Morning Post | Omicron and the Winter Olympics – is China’s zero-Covid strategy up to the challenges?
National Geographic | Omicron is dodging the immune system—but boosters show promising signs
Khaleej Times | Covid: 96% of people in low-income nations have yet to receive first vaccine dose, says expert
Voice of America | South Korea Showed How to Contain COVID, Now It Will Try to Live With It
South China Morning Post | Next Covid-19 test? Diagnostic blind spots stir visions of bleak midwinter
South China Morning Post | US-China coronavirus vaccine diplomacy heats up but can donations sway allegiances?
South China Morning Post | Coronavirus: as rich countries turn to big-name booster shots from Pfizer, AstraZeneca, the poor are left with lesser-known rivals like Abdala, Soberana 2
South China Morning Post | Coronavirus: China seeks to develop next-gen vaccines amid trial complications
South China Morning Post | Can China stay ahead as a leading exporter of Covid-19 vaccines?
Maeil Business Newspaper | All music is beautiful in its own way, but Violinist Sang Hee Lee’s music shines a special light
EIU Perspectives | What does Denmark’s permanent suspension of both the AstraZeneca and Janssen covid-19 vaccines mean for other countries?
South China Morning Post | Coronavirus vaccines will save 2021? Not so fast, here’s what the experts think
The Telegraph | ‘If you are not prepared, the virus has found every weakness’: How countries in Asia tamed Covid-19
Devex | Q&A: Why Jerome Kim is ‘hopeful’ but cautious about distributing a COVID-19 vaccine
Maeil Business Newspaper | IVI Director General Jerome Kim Shares His Thoughts on Resurgence of COVID-19 Outbreaks in S. Korea
Chosun Ilbo | IVI Director General Jerome Kim Shares His Thoughts on Equitable Access of COVID-19 Vaccines
Channel News Asia | On a fast track like never before: The COVID-19 vaccine effort and 5 vital questions
The Economist’s Future of Healthcare Insight Hour | Vaccine development: A race to the finish line
CNBC | Parts of Asia that relaxed restrictions without a resurgence in coronavirus cases did these three things
The Korea Herald | [Herald Interview] ‘Making vaccines accessible is biggest COVID-19 challenge’
ANC 24/7 | Int’l Vaccine Institute: 12-18 months reasonable timetable for development of Covid-19 vaccine
Wion News | About 70% of vaccines used around the world are made in India: S Korean expert Dr Jerome Kim
South China Morning Post | How long will a coronavirus vaccine take? A Q&A with Jerome Kim, head of the International Vaccine Institute
Development of vaccine requires massive investment… international cooperation is needed (Korea Economic Daily)
Coronavirus Pandemic: International Vaccine Institute director on how long it will take to develop vaccine (CGTN)
How close are we to a COVID-19 vaccine? Jerome H. Kim from International Vaccine Institute (Arirang News)
Jerome Kim for Korea, Factual: “Hong Kong’s handling of COVID-19 outbreak & Prospects of vaccine development”
Concerns about the spread of COVID-19: When will a vaccine be developed? When can we expect the “Super Vaccine”?
Most dengue infections transmitted in and around home
- Findings published in Science provide insight into how dengue spreads
- IVI ‘s Dr. In-Kyu Yoon co-authors study
March 21, 2017 - Outbreaks of the dengue virus appear to be largely driven by infections centered in and around the home, with the majority of cases related to one another occurring in people who live less than 200 meters apart, suggests new research led by the University of Florida, the Institut Pasteur, Walter Reed Army Institute of Research, the Ministry of Public Health of Thailand, the Queen Sirikit National Institute of Child Health and the Johns Hopkins Bloomberg School of Public Health. The International Vaccine Institute’s (IVI) Dr. In-Kyu Yoon, also Director of the Global Dengue & Aedes-Transmitted Diseases Consortium (GDAC), is among the co-authors. He previously was Chief of Virology at the Armed Forces Research Institute of Medical Sciences in Bangkok, Thailand.
The findings, published in the March 24 issue of Science, offer new insights into the spread of dengue — which infects more than 300 million people each year — and other flaviviruses such as Zika and yellow fever, and how governments and individuals might put in place more targeted and more effective mosquito control programs.
For their study, the researchers genetically sequenced the viruses of 640 dengue infections that occurred between 1994 and 2010 in both densely-populated Bangkok, Thailand and less densely populated regions outside the capital, then overlaid this information on a map showing where the people infected with the virus lived. Their results show that in people living fewer than 200 meters apart (typically in houses in the same neighborhood), 60 percent of dengue cases come from the same transmission chain, meaning they were infected by a virus that was only recently introduced into the area. In people who were separated by one to five kilometers, just three percent of cases came from the same transmission chain.
Forty percent of the world’s population live in areas where they are at risk for dengue, which is most common in Southeast Asia and the western Pacific islands and has been rapidly increasing in Latin America and the Caribbean. While most of the 300 million people who get dengue annually survive with few or no symptoms, more than two million per year develop more severe dengue, which kills more than 25,000 people each year — mostly children.
The researchers analyzed the genetic diversity of dengue viruses across Bangkok. They estimate that 160 separate chains of transmission co-circulate in Bangkok within a “dengue season,” which in Thailand is usually June to November. Across the city, they found that larger populations of humans support a larger diversity of dengue viruses.
“These findings are significant since they provide empirical evidence of the
importance of home location in dengue virus transmission,” said Dr. In-Kyu Yoon, IVI’s Deputy Director General of Science. “In addition, they highlight the role of population centers as important sources of dengue virus diversity.”
The research was supported by grants from the National Institutes of Health’s National Institute of Allergy and Infectious Diseases (R01AI114703-01 and R01 AI102939-01A1), the National Science Foundation (BCS-1202983) and the Global Emerging Infections Surveillance and Response System, a Division of the Armed Forces Health Surveillance Health Center.
About the International Vaccine Institute
The International Vaccine Institute (IVI) is the world’s only international organization devoted exclusively to developing and introducing new and improved vaccines to protect the world’s poorest people, especially children in developing countries. Established in 1997, IVI operates as an independent international organization under a treaty signed by 35 countries and the World Health Organization. The Institute conducts research in more than 20 countries of Asia, Africa and Latin America on vaccines against enteric and diarrheal infections, Japanese encephalitis, MERS-CoV, and dengue fever, and develops new and improved vaccines at its headquarters in Seoul, Republic of Korea. For more information, please visit http://www.ivi.int .
Tae Kyung Byun, IVI